378 related articles for article (PubMed ID: 32590976)
21. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
Chaves-Markman ÂV; Markman M; Calado EB; Pires RF; Santos-Veloso MAO; Pereira CMF; Lordsleem ABMDS; Lima SG; Markman Filho B; Oliveira DC
Arq Bras Cardiol; 2019 Jul; 113(1):77-84. PubMed ID: 31291414
[TBL] [Abstract][Full Text] [Related]
22. Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly).
Lau K; Üçeyler N; Cairns T; Lorenz L; Sommer C; Schindehütte M; Amann K; Wanner C; Nordbeck P
Mol Genet Genomic Med; 2022 May; 10(5):e1912. PubMed ID: 35212486
[TBL] [Abstract][Full Text] [Related]
23. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
24. Clinical, histological and molecular characteristics of Mexican patients with Fabry disease and significant renal involvement.
Ramos-Kuri M; Olvera D; Morales JJ; Rodriguez-Espino BA; Lara-Mejía A; De Los Ríos D; Obrador GT; Granados J; Correa-Rotter R
Arch Med Res; 2014 Apr; 45(3):257-62. PubMed ID: 24656905
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
[TBL] [Abstract][Full Text] [Related]
26. Fabry disease due to D313Y and novel GLA mutations.
Koulousios K; Stylianou K; Pateinakis P; Zamanakou M; Loules G; Manou E; Kyriklidou P; Katsinas C; Ouzouni A; Kyriazis J; Speletas M; Germenis AE
BMJ Open; 2017 Oct; 7(10):e017098. PubMed ID: 28988177
[TBL] [Abstract][Full Text] [Related]
27. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
28. Use of a rare disease registry for establishing phenotypic classification of previously unassigned
Germain DP; Oliveira JP; Bichet DG; Yoo HW; Hopkin RJ; Lemay R; Politei J; Wanner C; Wilcox WR; Warnock DG
J Med Genet; 2020 Aug; 57(8):542-551. PubMed ID: 32161151
[TBL] [Abstract][Full Text] [Related]
29. Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene.
Gervas-Arruga J; Cebolla JJ; Irun P; Perez-Lopez J; Plaza L; Roche JC; Capablo JL; Rodriguez-Rey JC; Pocovi M; Giraldo P
BMC Genet; 2015 Sep; 16():109. PubMed ID: 26334996
[TBL] [Abstract][Full Text] [Related]
30. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
31. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.
Nowak A; Mechtler TP; Desnick RJ; Kasper DC
Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.
Zhou C; Huang J; Cui G; Zeng H; Wang DW; Zhou Q
BMC Med Genet; 2018 Dec; 19(1):219. PubMed ID: 30587147
[TBL] [Abstract][Full Text] [Related]
33. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
[TBL] [Abstract][Full Text] [Related]
34. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Chen Z; Yin B; Jiao J; Ye T
BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
[TBL] [Abstract][Full Text] [Related]
35. Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: an observational study in Brazilian patients.
Varela P; Mastroianni Kirsztajn G; Motta FL; Martin RP; Turaça LT; Ferrer HLF; Gomes CP; Nicolicht P; Mara Marins M; Pessoa JG; Braga MC; D'Almeida V; Martins AM; Pesquero JB
Orphanet J Rare Dis; 2020 Jan; 15(1):30. PubMed ID: 31996269
[TBL] [Abstract][Full Text] [Related]
36. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
Lenders M; Weidemann F; Kurschat C; Canaan-Kühl S; Duning T; Stypmann J; Schmitz B; Reiermann S; Krämer J; Blaschke D; Wanner C; Brand SM; Brand E
Orphanet J Rare Dis; 2016 May; 11(1):54. PubMed ID: 27142856
[TBL] [Abstract][Full Text] [Related]
37. No evidence of Fabry disease in a patient with the new p.Met70Val GLA gene variant.
Capelli I; Di Costanzo R; Aiello V; Lerario S; De Giovanni P; Montevecchi M; Cerretani D; Donadio V; La Manna G; Mignani R
Mol Genet Genomic Med; 2024 Jun; 12(6):e2390. PubMed ID: 38895855
[TBL] [Abstract][Full Text] [Related]
38. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
[TBL] [Abstract][Full Text] [Related]
39. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.
Kobayashi M; Ohashi T; Fukuda T; Yanagisawa T; Inomata T; Nagaoka T; Kitagawa T; Eto Y; Ida H; Kusano E
Mol Genet Metab; 2012 Dec; 107(4):711-5. PubMed ID: 23146289
[TBL] [Abstract][Full Text] [Related]
40. Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report.
Rodríguez Doyágüez P; Furlano M; Ars Criach E; Arce Y; Guirado L; Torra Balcells R
Nefrologia (Engl Ed); 2023 Dec; 43 Suppl 2():91-95. PubMed ID: 38278716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
